Financial

Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer

Dr. Pamela Bush Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer EAGAN, Minn., Feb. 03, 2023 (GLOBE…

1 year ago

Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue…

1 year ago

Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force

Continuing to Explore Strategic Alternatives CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”)…

1 year ago

BenchSci Announces Launch of ASCEND™ – a First-of-its-Kind ‘Map’ of All Disease Biology that Aims to Transform Pharmaceutical Research

The SaaS solution is powered by proprietary machine-learning technology that reads and interprets data like a PhD scientist BenchSci ASCEND…

1 year ago

DiagnaMed Holdings Provides Update for BRAIN AGE™ Development and Commercialization Milestones for 2023

Complete IRB-approved research study in Q2-2023 Commercialize BRAIN AGE™ in Q4-2023 TORONTO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings…

1 year ago

Precision Neuroscience Raises $41 Million to Build and Scale the Next Generation of Treatments for Neurological Illnesses

The brain–computer interface company advances the industry with plans for a minimally invasive, reversible implant.NEW YORK, Jan. 25, 2023 (GLOBE…

1 year ago

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance…

1 year ago

CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal

Collaboration will support Sanofi’s use of CytoReason’s computational disease models to develop new targets for inflammatory bowel disease (IBD)TEL AVIV,…

1 year ago

OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma

Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients Data reinforce the…

1 year ago

Castellum, Inc. Announces Signing of Non-Binding LOI for East Coast Government Contractor

Castellum, Inc. Announces Signing of Non-Binding LOI for East Coast Government Contractor Castellum, Inc. (NYSE-American: CTM), a cybersecurity, electronic warfare,…

2 years ago